Dashboard
Manage Tickers

RIGL


   

CLICK TO SEE RELEVANT LITIGATION UPDATES
QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

Core News & Articles
12 Health Care Stocks Moving In Wednesday'...
11/05/2025 17:05:53

johnson-controls-babcock--wilcox-lemonade-lumentum-teva-pharmaceutical-and-other-big-stocks-moving-higher-on-wednesday
Johnson Controls, Babcock & Wilcox, Lemona...
11/05/2025 16:56:53

cantor-fitzgerald-maintains-neutral-on-rigel-pharmaceuticals-raises-price-target-to-38
Cantor Fitzgerald Maintains Neutral on Rig...
11/05/2025 15:48:14

Cantor Fitzgerald analyst Kristen Kluska maintains Rigel Pharmaceuticals (NASDAQ:RIGL) with a Neutral and raises the price t...

Core News & Articles
12 Health Care Stocks Moving In Wednesday'...
11/05/2025 12:05:48

why-teradata-shares-are-trading-higher-by-around-15-here-are-20-stocks-moving-premarket
Why Teradata Shares Are Trading Higher By ...
11/05/2025 10:09:59

Core News & Articles
12 Health Care Stocks Moving In Tuesday's ...
11/04/2025 21:06:29

rigel-pharmaceuticals-raises-fy2025-sales-guidance-from-210000m-220000m-to-285000m-290000m-vs-281095m-est
Rigel Pharmaceuticals Raises FY2025 Sales ...
11/04/2025 21:04:51

Rigel Pharmaceuticals (NASDAQ:RIGL) raises FY2025 sales outlook from $210.000 million-$220.000 million to $285.000 million-$290...

rigel-pharmaceuticals-q3-eps-146-beats-084-estimate-sales-69462m-beat-61880m-estimate
Rigel Pharmaceuticals Q3 EPS $1.46 Beats $...
11/04/2025 21:03:46

Rigel Pharmaceuticals (NASDAQ:RIGL) reported quarterly earnings of $1.46 per share which beat the analyst consensus estimate of...

earnings-scheduled-for-november-4-2025
Earnings Scheduled For November 4, 2025
11/04/2025 11:12:08

a-look-ahead-rigel-pharmaceuticalss-earnings-forecast
A Look Ahead: Rigel Pharmaceuticals's Earn...
11/03/2025 19:03:11

rigel-pharma-announces-first-patient-enrolled-in-dose-expansion-phase-of-ongoing-phase-1b-study-of-r2891-in-patients-with-rr-lower-risk-mds-earlier-today
Rigel Pharma Announces First Patient Enrol...
10/08/2025 14:29:09

Dose expansion phase will determine the recommended Phase 2 dose of R289 for patients with transfusion dependent R/R lower-risk...

hc-wainwright--co-reiterates-buy-on-rigel-pharmaceuticals-maintains-57-price-target
HC Wainwright & Co. Reiterates Buy on Rige...
10/08/2025 14:19:07

HC Wainwright & Co. analyst Joseph Pantginis reiterates Rigel Pharmaceuticals (NASDAQ:RIGL) with a Buy and maintains $57...

freeport-mcmoran-harmony-biosciences-cohu-and-other-big-stocks-moving-lower-on-wednesday
Freeport-McMoRan, Harmony Biosciences, Coh...
09/24/2025 18:18:13

cantor-fitzgerald-maintains-neutral-on-rigel-pharmaceuticals-raises-price-target-to-32
Cantor Fitzgerald Maintains Neutral on Rig...
08/06/2025 14:12:29

Cantor Fitzgerald analyst Kristen Kluska maintains Rigel Pharmaceuticals (NASDAQ:RIGL) with a Neutral and raises the price t...

rigel-pharmaceuticals-q2-eps-328-beats-019-estimate-sales-101685m-beat-48142m-estimate
Rigel Pharmaceuticals Q2 EPS $3.28 Beats $...
08/05/2025 20:11:24

Rigel Pharmaceuticals (NASDAQ:RIGL) reported quarterly earnings of $3.28 per share which beat the analyst consensus estimate of...

rigel-pharmaceuticals-raises-fy2025-sales-guidance-from-200000m-210000m-to-210000m-220000m-vs-201095m-est
Rigel Pharmaceuticals Raises FY2025 Sales ...
08/05/2025 20:05:44

Rigel Pharmaceuticals (NASDAQ:RIGL) raises FY2025 sales outlook from $200.000 million-$210.000 million to $210.000 million-$220...

Core News & Articles
Earnings Scheduled For August 5, 2025
08/05/2025 08:32:54

what-to-expect-from-rigel-pharmaceuticalss-earnings
What to Expect from Rigel Pharmaceuticals'...
08/04/2025 20:06:18

rigel-pharmaceuticals-to-present-final-gavreto-phase-12-arrow-study-data-in-ret-fusion-positive-nsclc-and-solid-tumors-along-with-supportive-rezlidhia-data-for-midh1-rr-aml-at-asco-and-eha-2025-conferences
Rigel Pharmaceuticals To Present Final GAV...
05/22/2025 21:36:10

Final data from the GAVRETO® (pralsetinib) Phase 1/2 ARROW study in RET fusion-positive NSCLC and other solid tumors  Supportiv...

rockwell-automation-posts-better-than-expected-earnings-joins-oscar-health-charles-river-laboratories-walt-disney-voya-financial-and-other-big-stocks-moving-higher-on-wednesday
Rockwell Automation Posts Better-Than-Expe...
05/07/2025 14:10:28

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION